Test Price
2,800 AED✅ Home Collection Available
SGCE Gene DYT11 (Myoclonus-Dystonia) Genetic Test in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
The SGCE Gene DYT11 NGS Sequencing test provides a definitive molecular diagnosis for myoclonus-dystonia syndrome using Next-Generation Sequencing technology. This certified diagnostic solution offers unmatched precision for hereditary movement disorder evaluation.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance with a DHA-licensed genetics consultant to interpret results.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This test leverages Next-Generation Sequencing (NGS) to analyse the entire coding region, splice sites, and known deep intronic mutations of the SGCE gene. It provides a comprehensive and definitive molecular diagnosis for myoclonus-dystonia syndrome (DYT11), enabling targeted therapeutic management and precise genetic counselling.
| Feature | Our Test (SGCE DYT11 NGS) | Closest Alternative (Targeted Sanger Panel) |
|---|---|---|
| Methodology | Next-Generation Sequencing (NGS) – full gene analysis | Sanger sequencing (single-exon or hotspot testing) |
| Coverage | Complete coding exons, splice sites, and known deep intronic mutations | Limited to specific, pre-selected mutations |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| Clinical Interpretation | Comprehensive report with genetic counselling integration & DHA guidelines | Basic mutation report without structured clinical guidance |
Physician Insight & Safety Protocols
“As a geneticist specializing in movement disorders, I understand the emotional weight of seeking a molecular diagnosis for myoclonus-dystonia. A positive SGCE DYT11 result provides a clear explanation, but your clinical journey is unique. This test empowers your neurologist to tailor therapy and provide the safest, most effective care.”
— Consultant Medical Genetics Lina Osama Zaki Quteineh, DHA Registration ID: 9294403
Important Advisory
Do not discontinue prescribed medication without consulting your physician. This genetic test is for diagnostic confirmation and clinical guidance, not for unsupervised treatment modification.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Recent allogeneic bone marrow transplant may confound DNA analysis; sample collection is deferred for six months post-transplant.
- Exclusion: Active chemotherapy that could degrade sample quality; consult oncologist before collecting blood.
- Red Flag: Sudden severe worsening of dystonia causing respiratory distress or inability to swallow — seek emergency care immediately.
- Red Flag: New-onset status myoclonus unresponsive to home management — proceed to the nearest emergency department.
Patient FAQ & Clinical Guidance
1. What is the SGCE gene DYT11 Genetic Test and what does it detect?
This test precisely sequences the entire coding region of the SGCE gene using Next-Generation Sequencing to identify pathogenic variants causing myoclonus-dystonia syndrome (DYT11), a hereditary movement disorder. The test provides a definitive molecular diagnosis with 99.9% sensitivity.
2. How is the sample collected and can it be done at home?
A simple, virtually painless blood draw or saliva sample is collected by our DHA-licensed phlebotomist during your VIP home visit within the Temperature-Controlled Cold-Chain logistics framework. Home collection is available daily from 8 AM to 11 PM.
3. When will I receive results and what should I expect in the report?
Results are delivered in 3–4 weeks with a clear, actionable report including variant interpretation, clinical correlation, and precise genetic counselling recommendations integrated with DHA clinical guidelines.
UAE Regulatory & Data Privacy Adherence
This testing process and data handling are fully compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
DNA Labs UAE operates under DHA Facility License Number: 1143, ensuring all diagnostic processes meet the highest standards of clinical accuracy and patient safety in Dubai Healthcare City.
Clinical & Logistical Metadata
| Test Name | SGCE Gene DYT11 NGS Sequencing |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Blood, Saliva (Oragene OG-500), or FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS), Full Gene Analysis |
| ICD-10-CM Code | G24.8 |
| LOINC Code | 97961-3 |
| DHA Facility License & Address | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DHA License: 1143 |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians